Skip to Content

Press Releases

Press Releases

Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
October 16, 2019
SOUTH SAN FRANCISCO, Calif. , Oct. 16, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held Oct. 26-30, 2019 , in Boston .
Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress
June 15, 2019
- Interim results show STRO-001 was generally well tolerated and anti-tumor activity was observed in two patients with recurrent diffuse large B-cell lymphoma (DLBCL) - STRO-001 is the first antibody-drug conjugate generated with Sutro's novel cell-free protein synthesis technology and
Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference
January 3, 2019
SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell , Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 10, 2019 at 11:30 a.m. PT / 2:30 p.m. ET at the Westin St.